Placebo News and Research

RSS

Clinical research trial of new treatment to restore brain cells damaged by stroke passes safety stage

A clinical research trial of a new treatment to restore brain cells damaged by stroke has passed an important safety stage, according to the UC Irvine neurologist who led the effort.

11 Mar 2010

Clinical trial shows eprotirome drug reduces blood cholesterol

A thyroid-hormone-like substance that works specifically on the liver reduces blood cholesterol with no serious side effects. This according to a clinical trial conducted by researchers from the Swedish medical university Karolinska Institutet, amongst other centres, published today in the top-ranking scientific periodical The New England Journal of Medicine.

11 Mar 2010

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

NeuroSearch today announced that further analysis of the data from the MermaiHD study with Huntexil(R) (pridopidine) for the treatment of Huntington's disease supports potential disease modifying properties of the drug.

11 Mar 2010

Small study shows eprotirome decreases LDL cholesterol

People whose "bad" cholesterol and risk of future heart disease stay too high despite cholesterol-lowering statin therapy can safely lower it by adding a drug that mimics the action of thyroid hormone. In a report published in the Mar. 11, issue of the New England Journal of Medicine, Johns Hopkins and Swedish researchers say an experimental drug called eprotirome lowered cholesterol up to 32 percent in those already on statins, an effect equal to that expected from doubling the statin drug doses, without harmful side effects.

10 Mar 2010

DSPA's lurasidone NDA accepted for FDA review

Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.

10 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Few CE studies compare medications with nonpharmacologic interventions, and examine safety or cost-effectiveness

An analysis of comparative effectiveness studies finds that few compare medications with nonpharmacologic interventions, and few examine safety or cost-effectiveness, according to a study in the March 10 issue of JAMA.

10 Mar 2010

Study provides first formal analysis of comparative effectiveness research on new therapies

An analysis by researchers at the Keck School of Medicine of the University of Southern California has found that only 32 percent of medication studies published in top medical journals compare the effectiveness of existing treatments. These studies, known as comparative effectiveness studies, help doctors know which therapies work best and under what circumstances they are most effective.

10 Mar 2010

Augmentation with ketone bodies improves cognitive function in AD patients

Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced data which showed that augmentation with ketone bodies significantly improved cognitive function in Alzheimer's disease (AD) patients.

10 Mar 2010

Diamyd Medical enrolls over 430 children with newly diagnosed type 1 diabetes in global Phase III program

Diamyd Medical announces today that one hundred study participants have been included in the ongoing US Phase III study, DiaPrevent. The global Phase III program with the company’s lead drug candidate Diamyd® has thereby enrolled more than 430 children newly diagnosed with type 1 diabetes in Europe and the USA.

10 Mar 2010

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the “Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus” trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

10 Mar 2010

Researchers to collaborate on the largest clinical trial of hypothermia for stroke

Researchers at Cedars-Sinai Medical Center in Los Angeles, the University of California, San Diego School of Medicine, and UTHealth's Medical School will collaborate on the largest clinical trial of hypothermia (brain cooling) for stroke to date.

10 Mar 2010

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

9 Mar 2010

FDA approves BOTOX for treatment of increased muscle stiffness in adults with upper limb spasticity

Allergan, Inc. today announced that the United States Food and Drug Administration has approved BOTOX® (onabotulinumtoxinA) for the treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper limb spasticity.

9 Mar 2010

Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury

Ischemix today announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule.

9 Mar 2010

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

9 Mar 2010

Study: Effects of testosterone on human behavior in 'pro-social' situation

Is aggression always the best response to a challenge? Testosterone may not necessarily cause aggression but behavior can drive testosterone secretion.

9 Mar 2010

Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK

The Journal of the American Academy of Dermatology (JAAD) has published Phase III data evaluating the safety and efficacy of imiquimod cream at two doses - 2.5% and 3.75% - administered daily on a 2-week treatment cycle. The study demonstrates that both formulations were superior to placebo, and that imiquimod 3.75% on a daily 2-week treatment cycle is superior to imiquimod 2.5% in treating actinic keratosis (AK) on a large surface area - the face or balding scalp.

9 Mar 2010

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

The Journal of the American Academy of Dermatology has published Phase III data evaluating the safety and efficacy of imiquimod cream at two doses – 2.5% and 3.75% – administered daily on either 2-week or 3-week treatment cycles.

9 Mar 2010

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.

9 Mar 2010

Placebo News and Research

Clinical research trial of new treatment to restore brain cells damaged by stroke passes safety stage

Clinical trial shows eprotirome drug reduces blood cholesterol

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

Small study shows eprotirome decreases LDL cholesterol

DSPA's lurasidone NDA accepted for FDA review

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Few CE studies compare medications with nonpharmacologic interventions, and examine safety or cost-effectiveness

Study provides first formal analysis of comparative effectiveness research on new therapies

Augmentation with ketone bodies improves cognitive function in AD patients

Diamyd Medical enrolls over 430 children with newly diagnosed type 1 diabetes in global Phase III program

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Researchers to collaborate on the largest clinical trial of hypothermia for stroke

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

FDA approves BOTOX for treatment of increased muscle stiffness in adults with upper limb spasticity

Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Study: Effects of testosterone on human behavior in 'pro-social' situation

Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News